Francis P. Arena

Oncology | Hematology

1999 Marcus Avenue
Suite 308
New Hyde Park, NY 11042

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Linguistic and content validation of the translated and culturally adapted patient-generated subjective global assessment (PG-SGA).

Linguistic and content validation of the translated and culturally adapted patient-generated subjective global assessment (PG-SGA).

Journal: Clinical nutrition ESPEN

Published: November 07, 2022

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment.

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 11, 2022

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.

Journal: ESMO open

Published: May 30, 2022

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.

Journal: ESMO open

Published: January 29, 2022

Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.

Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.

Journal: ESMO open

Published: November 03, 2021

A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.

A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.

Journal: ESMO open

Published: July 21, 2021

Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment†.

Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment†.

Journal: ESMO open

Published: July 21, 2020

Critical Aspects of a Sustainable Clinical Research Program in the Community-Based Oncology Practice.

Critical Aspects of a Sustainable Clinical Research Program in the Community-Based Oncology Practice.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 18, 2019

Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.

Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.

Journal: Current treatment options in gastroenterology

Published: October 07, 2016

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer.

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer.

Journal: Journal of Cancer

Published: February 29, 2016

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 23, 2015

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 01, 2015

Showing 1-12 of 22

Last Updated: 09/26/2026